Travade P
Service des Maladies Infectieuses et Tropicales et d'Hématologie Clinique, Hôtel-Dieu, Clermont-Ferrand, France.
Nouv Rev Fr Hematol (1978). 1990;32(5):313-7.
This paper summarizes results from clinical trials of the French Cooperative Group in chronic lymphocytic leukemia, CLL 80 and CLL 85 protocols. These protocols were based on the (A, B, C) classification. Nine hundred and seventy three patients were randomised in the CLL 80 protocol, 612 in stage A, 289 in stage B and 72 in stage C. Results from the fourth interim analysis were (1) in stage A, overall survival was better in the untreated group as compared to patients treated by daily chlorambucil with an increased incidence of epithelial cancers in the chlorambucil group; (2) in stage B, there was no improvement in overall survival with the COP regimen as compared to daily chlorambucil; (3) in stage C, the effectiveness of the CHOP regimen was confirmed. More than 1,400 patients have been randomised in the CLL 85 protocol but results from the first interim analysis were only available in stage B (194 patients). At the 6-month evaluation 28% reached complete remission in the CHOP group versus 12% in the chlorambucil-prednisone group. More follow-up is needed to assess the benefit from the CHOP regimen in terms of survival in stage B patients.
本文总结了法国慢性淋巴细胞白血病协作组CLL 80和CLL 85方案的临床试验结果。这些方案基于（A、B、C）分类。973例患者被随机分配至CLL 80方案，其中612例为A期，289例为B期，72例为C期。第四次中期分析结果为：（1）在A期，未治疗组的总生存期优于每日使用苯丁酸氮芥治疗的患者，且苯丁酸氮芥组上皮癌发病率增加；（2）在B期，与每日使用苯丁酸氮芥相比，COP方案未改善总生存期；（3）在C期，CHOP方案的有效性得到证实。超过1400例患者被随机分配至CLL 85方案，但首次中期分析结果仅在B期（194例患者）可用。在6个月评估时，CHOP组28%达到完全缓解，而苯丁酸氮芥-泼尼松组为12%。需要更多随访以评估CHOP方案对B期患者生存的益处。
